Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Amortizatization of Intangibles (2020 - 2025)

Historic Amortizatization of Intangibles for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $1.0 million.

  • Lyell Immunopharma's Amortizatization of Intangibles fell 7187.06% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 5454.3%. This contributed to the annual value of $14.7 million for FY2024, which is 5299.08% up from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Amortizatization of Intangibles is $1.0 million, which was down 7187.06% from $1.2 million recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Amortizatization of Intangibles high stood at $4.4 million for Q1 2024, and its period low was -$552000.0 during Q3 2021.
  • Over the past 5 years, Lyell Immunopharma's median Amortizatization of Intangibles value was $1.2 million (recorded in 2022), while the average stood at $1.4 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Amortizatization of Intangibles crashed by 19837.84% in 2021, and later surged by 99826.84% in 2023.
  • Quarter analysis of 5 years shows Lyell Immunopharma's Amortizatization of Intangibles stood at -$467000.0 in 2021, then soared by 358.67% to $1.2 million in 2022, then soared by 180.13% to $3.4 million in 2023, then dropped by 12.38% to $3.0 million in 2024, then plummeted by 65.97% to $1.0 million in 2025.
  • Its Amortizatization of Intangibles stands at $1.0 million for Q3 2025, versus $1.2 million for Q2 2025 and $1.7 million for Q1 2025.